This post was just published on ZYX Short Sell Change Alert.
ACOR is short from $48.73. The stock was halted at $20.33, down $6.44. The stock was being crushed before the halt as patents on Ampyra are invalidated. ACOR came to fame on Ampyra, a drug that marginally helps MS patients’ walking.
We have a long history with shorting this stock.
Before the halt the stock had fallen into the target zone of $14 to $21. 20% of the full core position size is being held.
What To Do Now
If the stock opens lower or right around the close before the halt, depending upon your account size, consider taking profits on one-quarter to one-half of your position.
For those not in the stock, consider waiting for a signal on the Real Time Feed.
Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007. Please click here and scroll down to see the table of all trades. These trades have been scrutinized in real-time by thousands of subscribers across the globe. This provides easy verification of performance for newcomers to this site. Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog. When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table. There are very nice gains on this trade but since the entry trade was not posted here in real-time, handsome profits on this trade will not be added to the performance of The Arora Report Market Blog shown on the table.
You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.